Rectal Cancer Staging and Management

Diagnostic Workup

• The European Society for Medical Oncology recommends rectal MRI for most tumors, and endoscopic ultrasound for early cT1-T2 lesions, to determine the depth of invasion, nodal status, and circumferential resection margin involvement, with treatment decisions based on these factors to minimize local recurrence and preserve sphincter function 1, 2
• Clinical rectal examination with rigid proctoscopy and biopsy is necessary for histopathological confirmation, according to the European Society for Medical Oncology 3, 1
• Tumors ≤15 cm from the anal verge are classified as rectal, as defined by the European Society for Medical Oncology 1, 4
• Complete colonoscopy is recommended to exclude synchronous lesions, as suggested by the European Society for Medical Oncology 1, 5

Staging Investigations

• Laboratory and imaging studies, including complete blood count, liver and renal function tests, carcinoembryonic antigen (CEA) level, chest imaging, and CT or MRI of abdomen/liver, are necessary for staging, according to the European Society for Medical Oncology 3, 1, 2

TNM Staging System

• The American Joint Committee on Cancer recommends using TNM version 7 (2010) or later for staging, with T stage classification including T1 (tumor invades submucosa), T2 (tumor invades muscularis propria), T3 (tumor invades through muscularis propria into perirectal tissues), and T4 (tumor invades adjacent organs or perforates visceral peritoneum) 1, 2
• N stage classification includes N0 (no regional lymph node metastases), N1 (1-3 regional lymph nodes involved), and N2 (≥4 regional lymph nodes involved), as defined by the American Joint Committee on Cancer 2

Treatment Algorithm Based on Staging

• For very early disease (T1 sm1-2, N0), local excision (transanal endoscopic microsurgery) is appropriate if there is no vessel invasion, the tumor is well or moderately differentiated, and complete resection with safe margins is achieved, according to the National Comprehensive Cancer Network 6
• For early favorable disease (cT1-2, some early cT3, N0), surgery alone using total mesorectal excision (TME) without neoadjuvant therapy is recommended, as suggested by the National Comprehensive Cancer Network 7, 6
• For intermediate risk (most cT3 without threatened mesorectal fascia, N+), preoperative radiotherapy followed by immediate TME surgery is recommended, according to the European Society for Medical Oncology 4, 5, 7
• For locally advanced disease (cT3 with threatened CRM, cT4), preoperative chemoradiotherapy is mandatory, with 50 Gy in 1.8 Gy fractions with concurrent 5-FU-based chemotherapy, and surgery delayed 6-8 weeks after completion, as recommended by the European Society for Medical Oncology 3, 7, 6

Surgical Approach

• Total mesorectal excision (TME) with sharp dissection is the standard surgical technique for all rectal cancers not amenable to local excision, according to the European Society for Medical Oncology 4, 5, 6

Postoperative Management

• Adjuvant chemotherapy should be considered for stage III disease, though evidence is less robust than for colon cancer, as suggested by the National Comprehensive Cancer Network 8, 7
• Postoperative chemoradiotherapy is no longer routinely recommended but reserved for positive circumferential margins, tumor perforation, or high risk of local recurrence when preoperative radiotherapy was not given, according to the European Society for Medical Oncology 3, 5, 8

Metastatic Disease (Stage IV)

• Resection of liver or lung metastases should be considered as part of curative-intent treatment in selected cases, according to the European Society for Medical Oncology 4, 6
• First-line palliative chemotherapy includes 5-FU/leucovorin combined with oxaliplatin or irinotecan, as recommended by the European Society for Medical Oncology 4, 6

Physical Examination Guidelines for Suspected Colorectal Cancer

Essential Examination Components

• Include a digital rectal examination (DRE) with rigid proctoscopy and obtain a biopsy, together with a complete abdominal examination for masses, hepatomegaly, and other signs of metastatic disease in any patient evaluated for possible colorectal cancer. 9, 10, 11

• Perform a thorough general physical assessment for anemia (e.g., pallor, tachycardia), cachexia, and peripheral lymphadenopathy in patients under investigation for colorectal malignancy. 9, 10, 11

• Check for clinical evidence of metastatic spread such as supraclavicular lymphadenopathy and ascites during the examination of suspected colorectal cancer cases. 9, 10

Tumor Localization and Measurement

• Use rigid proctoscopy—not flexible sigmoidoscopy—to measure the distance from the tumor to the anal margin; tumors ≤ 15 cm from the anal verge are classified as rectal cancer, whereas more proximal lesions are classified as colonic cancer. This measurement directly guides treatment planning (e.g., need for neoadjuvant therapy). 9, 10, 11

• Rigid proctoscopy provides the most accurate distance assessment, which is essential because the classification determines whether neoadjuvant chemoradiotherapy is indicated (rectal) or not (colon). 9, 10, 11

Biopsy Requirement

• Never postpone tissue biopsy based solely on clinical suspicion; histopathological confirmation must be obtained before initiating any therapeutic intervention for suspected colorectal cancer. 9, 10, 11

Assessment for Hepatic Metastasis

• During abdominal examination, actively palpate for hepatomegaly or discrete liver masses, as these findings suggest possible hepatic metastases in patients with suspected colorectal cancer. 9, 10, 11

Physical Examination Recommendations for Suspected Colorectal Cancer

Digital Rectal Examination (DRE) and Rigid Proctoscopy

• Perform a digital rectal examination to inspect and palpate the anus and lower rectum for masses, induration, or blood, as part of the initial assessment of any patient with suspected colorectal cancer. 12
• Conduct DRE during routine screening intervals of every 5–10 years in asymptomatic average‑risk adults; more frequent DRE does not improve detection of anal or rectal neoplasia. 12

Abdominal Examination

• Systematically palpate the abdomen for palpable masses, hepatomegaly, or discrete liver nodules that may indicate hepatic metastases. 13
• Assess for abdominal distension; a positive likelihood ratio of ≈ 16.8 for bowel obstruction supports the diagnosis of obstructive colorectal cancer when patients present with obstructive symptoms. 13
• Look for peritoneal signs (guarding, rebound tenderness, rigidity) that suggest perforation or ischemia and constitute surgical emergencies. 13
• Examine all hernia orifices (umbilical, inguinal, femoral) and prior surgical scars because incarcerated hernias can mimic or coexist with colorectal cancer‑related obstruction. 13

General Physical Assessment

• Evaluate for clinical signs of anemia (e.g., pallor, tachycardia, conjunctival pallor); approximately 57–60 % of patients with colorectal cancer present with anemia. 13
• Assess for cachexia, unintended weight loss, and overall nutritional status as markers of advanced disease. 13

Vital‑Sign and Hemodynamic Evaluation

• Measure heart rate, blood pressure, respiratory rate, and temperature to identify shock (tachycardia, tachypnea, hypotension) that may indicate bowel perforation, ischemia, or severe obstruction. 13
• Examine skin temperature, capillary refill, and mental status to detect hemodynamic compromise. 13

Examination in Elderly or Unconscious Patients

• When a thorough physical exam is limited by age or altered consciousness, prioritize assessment of vital signs and cardiopulmonary status to rapidly identify life‑threatening conditions. 13